Meeting
2023 ASCO Annual Meeting
Reporting of patient reported outcomes in randomized clinical trials (RCTs) in non-small cell lung cancer (NSCLC) patients (pts).
Authors
Laura Palmeri
Syneos Health, Farnborough, United Kingdom
Laura Palmeri , Sergii Derkach , Ewelina Mazur-Janik , Arundhati Soman , Catarina Ribeiro Alves , Radhika Shah , Liat Vidal-Fisher , Nahid Shahmarvand
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Quality Improvement
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6573)
DOI
10.1200/JCO.2023.41.16_suppl.6573
Abstract #
6573
Poster Bd #
65
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
TROP2 expression and response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer.
First Author: Antoine Italiano
Poster
2022 ASCO Annual Meeting
Association of progression-free survival and overall response rate with overall survival in first-line randomized trials of immune checkpoint inhibitor–based regimens for metastatic non–small cell lung cancer (NSCLC): An FDA pooled analysis.
First Author: Bernardo Haddock Lobo Goulart
Poster
2019 ASCO Annual Meeting
Reporting of patient reported outcome (PRO) in clinical trials: A systematic review of clinical trials.
First Author: Liat Vidal-Fisher
Poster
2024 ASCO Annual Meeting
Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations.
First Author: Melissa Lynne Johnson